Perrigo set to launch Nasonex 24HR Allergy in US

18 March 2022 - Deborah Wilkes


Perrigo has switched the allergy medicine Nasonex (mometasone furoate monohydrate) from prescription-to-OTC status in the US. Nasonex 24HR Allergy joins a small number of brands marketed by Perrigo in the US where it specialises in store-brand products.

Click tags below for more information on topics:


Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: